Search clinical trials for: biomedical outcomes

Total 1210 results

University of Chicago
National Cancer Institute (NCI)

Recruiting

Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer

Gastric Adenocarcinoma | Esophageal Adenocarcinoma | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric Cancer | Stage IIB Gastric Cancer | Stage IIIA Esophageal Adenocarcinoma | Stage IIIB Esophageal Adenocarcinoma | Stage IIIC Esophageal Adenocarcinoma

United States
University of Michigan Rogel Cancer Center
Bristol-Myers Squibb; Ipsen

Active, not recruiting

Phase Ib/II Trial of Nal-Irinotecan and Nivolumab as Second-Line Treatment in Patients With Advanced Biliary Tract Cancer

Biliary Tract Cancer

United States
Lyudmyla Berim

Active, not recruiting

Modified FOLFIRINOX Alternated With Biweekly Gemcitabine Plus Nab-Paclitaxel Untreated Pancreatic Cancer

Metastatic Pancreatic Cancer

United States
Bristol-Myers Squibb
AbbVie

Completed

An Investigational Immuno-therapy Study of Nivolumab, Pomalidomide and Dexamethasone Combinations in Patients With Multiple Myeloma (CheckMate 602)

Multiple Myeloma

Canada, United States, Israel, Czechia, Switzerland, Greece, Denmark, Portugal, Italy, Germany, Austria, Norway, Puerto Rico, Spain, Sweden, Turkey
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Unknown

ESK981 and Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IVB Prostate Cancer AJCC v8 | Castration Levels of Testosterone | Prostate Carcinoma Metastatic in the Bone

United States
Case Comprehensive Cancer Center

Completed

Assisted Exercise in Obese Endometrial Cancer Patients

Obesity | Uterine Cancer | Stage I Endometrial Adenocarcinoma

United States
Sheba Medical Center

Recruiting

Testing the Effectiveness of Two Hospitalization Alternatives Compared to Psychiatric Hospitalization (HOSP-ALT) (HOSP-ALT)

Data Collection | Questionnaires

Israel
Phanes Therapeutics
Merck Sharp & Dohme LLC

Recruiting

PT886 For Treatment of Patients With Metastatic/Advanced Gastric, Gastroesophageal Junction and Pancreatic Adenocarcinoma (the TWINPEAK Study)

Pancreatic Ductal Adenocarcinoma | Gastric or Gastroesophageal Junction Adenocarcinoma

United States
Merck Sharp & Dohme LLC

Recruiting

Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66)

Colorectal Neoplasms

China
Niko Kavcic

Completed

Evaluation of Intradetrusor AbobotulinumtoxinA and IncobotulinumtoxinA in Women With Overactive Bladder

Overactive Bladder

Slovenia
Weill Medical College of Cornell University
Boehringer Ingelheim

Completed

COVID-19 Respiratory Outcomes Registry

Covid19

United States
Halmstad County Hospital

Completed

Orally Administered Trimethoprim-sulfamethoxazole and Metronidazole as Prophylaxis of Infection Following Elective Colorectal Surgery

Infection Prophylaxis in Colo Rectal Surgery

Sweden
University Hospital, Basel, Switzerland

Recruiting

Occurrence of Antibodies Cross-reacting With Autoantigens in Primary EBV Infection

Epstein-Barr Virus (EBV) Infection

Switzerland
Merck Sharp & Dohme LLC

Recruiting

A Study of MK-1084 in KRAS Mutant Advanced Solid Tumors (MK-1084-001)

Advanced Solid Tumors

China, United States, Australia, Canada, Chile, Israel, Japan, Korea, Republic of, Panama, Poland, Spain, Switzerland, Turkey, New Zealand, Taiwan, Denmark, Italy
University of Saskatchewan

Not yet recruiting

Systemic Therapy With a Loco-regional Treatment in Patients With Locally Advanced Pancreatic Cancer (SMART)

Locally Advanced Pancreatic Cancer | Irreversible Electroporation
Academisch Medisch Centrum - Universiteit van Amsterdam...
Bristol-Myers Squibb

Recruiting

A Study of Mitomycin-c/ Capecitabine ChemoRadiotherapy Combined With Nivolumab Monotherapy or Ipilumimab and Nivolumab, as Bladder Sparing Curative Treatment for Muscle Invasive Bladder Cancer: the CRIMI Study (CRIMI)

Urinary Bladder Cancer | Invasive Bladder Cancer

Netherlands
National Cancer Institute (NCI)

Withdrawn

Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma

Cervical Carcinoma | Recurrent Melanoma | Vaginal Carcinoma | Esophageal Carcinoma | Mucosal Melanoma | Mucosal Melanoma of the Head and Neck | Oral Cavity Mucosal Melanoma | Stage II Vulvar Cancer AJCC v7 | Stage III Vulvar Cancer AJCC v7 | Stage IIIA Vulvar Cancer AJCC v7 | Stage IIIB Vulvar Cancer AJCC v7 and other conditions

United States
Shanghai Zhongshan Hospital

Not yet recruiting

Gut Microbiota Reconstruction for NSCLC Immunotherapy

Non-Small Cell Lung Cancer

China
Ipsen

Active, not recruiting

A Study to Compare Onivyde Manufactured at Two Different Production Sites in Adult Participants With Advanced Cancer in the Pancreas (SIRACUSA)

Metastatic Pancreatic Adenocarcinoma

Spain, Italy, Australia, Germany, France, Hungary, Portugal
Second Affiliated Hospital, School of Medicine,...

Active, not recruiting

Sequential Use of AG and mFOLFIRINOX as Neoadjuvant Chemotherapy for Resectable Pancreatic Cancer

Pancreatic Adenocarcinoma Resectable | Neoadjuvant Chemotherapy

China
Seagen Inc.

Active, not recruiting

A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression

Peripheral T-cell Lymphoma

United States, Czechia, Italy, Spain, United Kingdom, France
Jonsson Comprehensive Cancer Center
Bristol-Myers Squibb; National Cancer Institute (NCI); Vaccinex Inc.

Terminated

Anti-SEMA4D Monoclonal Antibody VX15/2503 With Nivolumab or Ipilimumab in Treating Patients With Stage III or IV Melanoma

Metastatic Melanoma | Stage III Cutaneous Melanoma AJCC v7 | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Stage IIIC Cutaneous Melanoma AJCC v7 | Stage IIIA Cutaneous Melanoma AJCC v7 | Stage IIIB Cutaneous Melanoma AJCC v7

United States
Dana-Farber Cancer Institute
Bristol-Myers Squibb

Withdrawn

An Exploratory Study to Evaluate the Combination of Elotuzumab and Nivolumab With and Without Pomalidomide in Relapsed Refractory Multiple Myeloma

Multiple Myeloma

United States
M.D. Anderson Cancer Center
Bristol-Myers Squibb

Withdrawn

Study of Lenalidomide/Dexamethasone With Nivolumab and Ipilimumab in Patients With Newly Diagnosed Multiple Myeloma

Multiple Myeloma | Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic
Northwell Health

Terminated

1/2-MC4R Genotype and Pediatric Antipsychotic Drug- Induced Weight Gain

High Risk MC4R Genotype | Low Risk MC4R Genotype | One Week or Less Antipsychotic Lifetime Exposure

United States
TriHealth Inc.

Completed

Diazepam Vaginal Suppositories for High Tone Pelvic Floor Dysfunction.

Female Patients With High Tone Pelvic Floor Dysfunction

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Recruiting

Testing the Addition of an Anti-Cancer Drug, Irinotecan, to the Standard Chemotherapy Treatment (FOLFOX) After Long-Course Radiation Therapy for Advanced-Stage Rectal Cancers to Improve the Rate of Complete Response and Long-Term Rates of Organ Preservation (JANUS)

Stage III Rectal Cancer AJCC v8 | Stage II Rectal Cancer AJCC v8 | Locally Advanced Rectal Carcinoma

United States, Puerto Rico
Sidney Kimmel Cancer Center at Thomas Jefferson...
Bristol-Myers Squibb

Completed

Nivolumab, Ipilimumab, and Radiation Therapy in Treating Patients With Stage III-IVB Head and Neck Cancer

Larynx | Lip, Oral Cavity and Pharynx

United States
National Cancer Institute (NCI)

Terminated

Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery

Metastatic Melanoma | Stage III Cutaneous Melanoma AJCC v7 | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Stage IIIC Cutaneous Melanoma AJCC v7 | BRAF V600E Mutation Present | BRAF V600K Mutation Present | Stage IIIA Cutaneous Melanoma AJCC v7 | Stage IIIB Cutaneous Melanoma AJCC v7

United States
Yonsei University

Active, not recruiting

Outcome in Patients Treated With Intraarterial Thrombectomy - optiMAL Blood Pressure Control (OPTIMAL-BP)

Ischemic Stroke

Korea, Republic of
National Institutes of Health Clinical Center (CC)
Emory University; Duke University

Completed

Trimethoprim-Sulfamethoxazole vs Levofloxacin as Targeted Therapy for Stenotrophomonas Maltophilia Infections: a Retrospective Cohort Study

Stenotrophomonas Infection

United States
University of Utah

Not yet recruiting

Hormonal Influences on Inflammatory Bowel Diseases

Inflammatory Bowel Diseases | Contraception | Menstrual Problem

United States
Thomas Jefferson University
Bristol-Myers Squibb

Active, not recruiting

Nivolumab and BMS986205 in Treating Patients With Stage II-IV Squamous Cell Cancer of the Head and Neck

Larynx | Squamous Cell Carcinoma | Lip | Oral Cavity Squamous Cell Carcinoma | Pharynx

United States
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Completed

An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)

Stage IV or Recurrent Non-Small Cell Lung Cancer

United States, Finland, Argentina, France, Italy, Brazil, Greece, Japan, Mexico, Romania, Spain, Sweden, United Kingdom, Australia, Austria, Belgium, Canada, Czechia, Germany, Hungary, Korea, Republic of, Netherlands, Poland, Switzerland and more
Washington University School of Medicine
Varian Medical Systems

Completed

SBRT (Stereotactic Body Radiation Therapy) vs. Surgery in High Risk Patients With Early Stage Lung Cancer

Non-Small Cell Lung Cancer | Nonsmall Cell Lung Cancer | Carcinoma, Non-Small-Cell-Lung

United States
University of North Carolina, Chapel Hill
National Heart, Lung, and Blood Institute (NHLBI)

Active, not recruiting

Just-in-time Adaptive Intervention Messaging in a Digital Weight Loss Intervention for Young Adults (Nudge)

Obesity | Overweight | Overweight and Obesity

United States
Lakehead University

Withdrawn

Effects of THC and Alcohol on Driving Performance

Alcohol Drinking | Cannabis | Accident, Traffic
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Recruiting

Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy

Nonsmall Cell Lung Cancer | Performance Status

United States
Aquestive Therapeutics
Covance; inVentiv Health Clinical

Completed

Study of Diazepam Buccal Film Administered in the Interictal and in the Ictal-Periictal States to Adults With Epilepsy

Epilepsy

United States
ERYtech Pharma

Completed

Efficacy and Safety of L-asparaginase Encapsulated in RBC Combined With Gemcitabine or FOLFOX in 2nd Line for Progressive Metastatic Pancreatic Carcinoma

Pancreatic Adenocarcinoma Metastatic

France
University of Wisconsin, Madison
Medical College of Wisconsin

Recruiting

Split-Dose R-CHOP for Older Adults With DLBCL

Cancer | Diffuse Large B Cell Lymphoma | DLBCL

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cancer

Metastatic Renal Cell Carcinoma | Metastatic Clear Cell Renal Cell Carcinoma | Advanced Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8 | Metastatic Sarcomatoid Renal Cell Carcinoma | Advanced Renal Cell Carcinoma | Unresectable Renal Cell... and other conditions

United States
National Cancer Centre, Singapore
Bristol-Myers Squibb

Withdrawn

Nivolumab in Combination With GDP/ L-asparaginase in NK/ T-cell Lymphoma

NK/T Cell Lymphoma

Singapore
Brian J Lipworth

Completed

Differential Trough Effects of 'Triple Therapy' on Pulmonary Function in Chronic Obstructive Pulmonary Disease (COPD) (FARD12)

COPD

United Kingdom
Seagen Inc.
Merck Sharp & Dohme LLC

Recruiting

A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer (MOUNTAINEER-03)

Colorectal Neoplasms

United States, Canada, Italy, Argentina, United Kingdom, China, Japan, Belgium, France, Korea, Republic of, Spain, Taiwan, Brazil, Ireland, Netherlands, Australia, Slovakia, Chile, Poland, Norway, Switzerland, Austria, Germany, Portugal, Gree... and more
Hoffmann-La Roche

Active, not recruiting

A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma

Lymphoma

United States, Spain, France, Netherlands, Poland, Denmark
Hoffmann-La Roche

Active, not recruiting

A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)

Pancreatic Adenocarcinoma

United States, Spain, Korea, Republic of, Germany, Japan
H. Lee Moffitt Cancer Center and Research Institute
Kite, A Gilead Company

Active, not recruiting

Axicabtagene Ciloleucel:Neurocognitive and Patient-Reported Outcomes

Diffuse Large B Cell Lymphoma | Transformed Lymphoma

United States
Merck Sharp & Dohme LLC

Active, not recruiting

Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension

Gastric Cancer | Gastroesophageal Junction Cancer

China
Astellas Pharma Global Development, Inc.

Completed

Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of ASP2215 in Patients With Relapsed or Refractory Acute Myeloid Leukemia

Acute Myeloid Leukemia

United States, Germany, Italy

Search clinical trials for: biomedical outcomes

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Belarus

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations